Roche and Zealand Pharma enter into a license agreement for the further development and commercialization of Petrelintide

...an amylin analog for the treatment of obesity. Zealand Pharma receives upfront payments and development milestones, while profits and losses are shared in the US and Europe.

$ROG (-5,6 %)
$ZEAL (-8,33 %)
$NOVO B (-6,66 %)